These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7908586)

  • 1. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
    Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
    Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
    Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L
    Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.
    Tefre T; Daly AK; Armstrong M; Leathart JB; Idle JR; Brøgger A; Børresen AL
    Pharmacogenetics; 1994 Apr; 4(2):47-57. PubMed ID: 8081413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.
    Evans WE; Relling MV; Rahman A; McLeod HL; Scott EP; Lin JS
    J Clin Invest; 1993 May; 91(5):2150-4. PubMed ID: 8098046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
    Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
    Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
    Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
    Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
    Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
    Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL; Huang JD; Lai MD; Liu BH; Lai ML
    Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
    Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
    Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
    Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.